Let's get acquainted

RxE2 is entirely revolutionizing how clinical trials are conducted by utilizing, for the first time ever, community pharmacists, powered by our cutting-edge technology that provides patient recruitment, dispensing, counseling, and operational services to the pharmaceutical and biotech industries.

A message from our CEO

I founded RxE2 to bring the practice of pharmacy to clinical trials. I am blessed to be surrounded by an unbelievable team of dedicated and experienced leaders. We make a difference, not incremental differences, but real differences in clinical trials.

We are committed to making clinical trials a viable healthcare option for Everyone, Everywhere™. With our new way of approaching industry problems, we can address the long-standing time, cost, and quality issues that have afflicted the industry for decades.

What can RxE2 do for you?

 

 

Gerald E. Finken

CEO & Pharmacist

Why we do it

We are devoted to solving clinical trial problems in the key areas of recruitment, adherence, compliance, and retention—all areas where RxE2 pharmacists shine. We have the expertise to create new and innovative solutions like our Patient Medication Journey and Pharmacy Access services. These are just two services we developed for local community pharmacists to deliver on clinical trials. With the next generation of drugs in the clinical trial pipeline, we must think outside the box to determine how to get these drugs approved and to market.

Clinical research is the key to developing new therapies and providing better medications for patients. We believe that community pharmacists are essential untapped resources – healthcare professionals who enjoy access to their community and know their patients best. We are enhancing these existing relationships between pharmacists and patients by using cutting-edge technology and putting pharmacists at the forefront of clinical research. This allows pharmacists to provide alternative treatment options to their patients and to take part in revolutionizing drug development.